The tumor cell-derived matrix of lobular breast cancer: a new vulnerability.
The tumor cell-derived matrix of lobular breast cancer: a new vulnerability.
复制标题
DOI：
10.15252/emmm.202013807
复制
发表时间：
2021-03-05
影响因子：
11.1
通讯作者：
Egan SE
中科院分区：
文献类型：
--
作者：
Kozma KJ;Done SJ;Egan SE
乳腺浸润性小叶癌是一种非常常见的疾病。尽管它的流行，这些肿瘤是相对研究不足。其中一个原因是国际劳工组织的模式相对缺乏。Brisken及其同事通过开发用于ERα+乳腺癌（包括ILC和更常见的浸润性导管癌）研究的导管内注射异种移植系统解决了这一挑战（IDC; Sflomos et al，2016）。在本期EMBO Molecular Medicine中，同一研究小组应用导管内注射异种移植物来鉴定ILC中新的肿瘤细胞特异性转录特征（Sflomos et al，2021）。在这样做的过程中，他们发现赖氨酰氧化酶样1（LOXL 1）的过表达是小叶乳腺癌中常见的富含胶原蛋白的细胞外基质的原因，也是其体内稳健生长和转移性扩散的关键，从而确定了一种新的治疗靶点。尽管其患病率，浸润性小叶癌（ILC）是相对研究不足。在他们最近的研究中，Brisken及其同事应用基于导管内注射的异种移植物来表征ILC中的肿瘤细胞特异性转录特征，并确定了一种新的治疗靶点。
Invasive lobular carcinoma (ILC) of the breast is a very common disease. Despite its prevalence, these tumors are relatively understudied. One reason for this is a relative lack of models for ILC. This challenge was addressed by Brisken and colleagues through development of an intraductal injection‐based xenograft system for the study of ERα+ breast cancers, including both ILC and more common invasive ductal carcinoma (IDC; Sflomos et al, 2016). In this issue of EMBO Molecular Medicine, the same group have applied intraductal injection‐based xenografts to identify novel tumor cell‐specific transcriptional signatures in ILC (Sflomos et al, 2021). In doing so they found overexpression of lysyl oxidase‐like 1 (LOXL1) to be both responsible for the frequently seen stiff collagen‐rich extracellular matrix of lobular breast cancer and essential for their robust growth and metastatic dissemination in vivo, thereby identifying a novel therapeutic target. Despite its prevalence, invasive lobular carcinoma (ILC) is relatively understudied. In their recent study, Brisken and colleagues apply intraductal injection based xenografts to characterize tumor‐cell specific transcriptional signatures in ILC and identify a novel therapeutic target.